Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Purpose: This study aimed to provide real-world evidence on the characteristics, treatment patterns, and outcomes of patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) treatment in Hungary between 2011 and 2019.Patients and methods: This nationwide, retrospective...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2024.1611497/full |
| _version_ | 1797222353917181952 |
|---|---|
| author | Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Zsolt Abonyi-Toth Judit Demeter |
| author_facet | Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Zsolt Abonyi-Toth Judit Demeter |
| author_sort | Peter Batar |
| collection | DOAJ |
| description | Purpose: This study aimed to provide real-world evidence on the characteristics, treatment patterns, and outcomes of patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) treatment in Hungary between 2011 and 2019.Patients and methods: This nationwide, retrospective study included patients who were newly diagnosed with CML in Hungarian clinical practice between January 2011 and December 2019. The analysis was based on the reimbursed prescription claims for imatinib, bosutinib, dasatinib, nilotinib, or ponatinib with the ICD-10 code C9210 in a public pharmacy between January 2009 and December 2019 using data from the National Health Insurance Fund (NHIF) of Hungary. CML incidence and prevalence, TKI treatment patterns, comorbidities, and overall survival (OS) were examined.Results: Between 2011 and 2019, altogether 1,407 patients were diagnosed with CML, with an annual average of 156 patients. The number of patients newly initiating first-line TKI therapy for CML significantly increased between 2011 and 2019 (2011: n = 136 vs. 2019: n = 191; p = 0.0043). Nilotinib was typically prescribed for younger patients (≤64 years), while older patients (≥65 years) mostly received imatinib. The most common comorbidity of CML patients was hypertension, and the proportion of patients with other malignancies was relatively high in all treatment groups. 5-year OS was 77.1% during the whole study period. Patients initiating first-line TKI treatment for CML in 2015 had significantly better 4-year OS compared to those starting treatment in 2011 (82.4% vs. 73.5%, respectively, (HR 0.53 (95%CI 0.32–0.87) p = 0.0118).Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations. |
| first_indexed | 2024-04-24T13:19:59Z |
| format | Article |
| id | doaj.art-0a06df27294a420cacee361560287976 |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T13:19:59Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-0a06df27294a420cacee3615602879762024-04-04T16:14:15ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072024-02-013010.3389/pore.2024.16114971611497Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from HungaryPeter Batar0Hussain Alizadeh1Gyorgy Rokszin2Zsolt Abonyi-Toth3Zsolt Abonyi-Toth4Judit Demeter5Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary1st Department of Medicine, Division of Haematology, Clinical Center, Medical School, University of Pecs, Pecs, HungaryRxTarget Ltd., Szolnok, HungaryRxTarget Ltd., Szolnok, HungaryDepartment of Biostatistics, University of Veterinary Medicine, Budapest, HungaryDepartment of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, HungaryPurpose: This study aimed to provide real-world evidence on the characteristics, treatment patterns, and outcomes of patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) treatment in Hungary between 2011 and 2019.Patients and methods: This nationwide, retrospective study included patients who were newly diagnosed with CML in Hungarian clinical practice between January 2011 and December 2019. The analysis was based on the reimbursed prescription claims for imatinib, bosutinib, dasatinib, nilotinib, or ponatinib with the ICD-10 code C9210 in a public pharmacy between January 2009 and December 2019 using data from the National Health Insurance Fund (NHIF) of Hungary. CML incidence and prevalence, TKI treatment patterns, comorbidities, and overall survival (OS) were examined.Results: Between 2011 and 2019, altogether 1,407 patients were diagnosed with CML, with an annual average of 156 patients. The number of patients newly initiating first-line TKI therapy for CML significantly increased between 2011 and 2019 (2011: n = 136 vs. 2019: n = 191; p = 0.0043). Nilotinib was typically prescribed for younger patients (≤64 years), while older patients (≥65 years) mostly received imatinib. The most common comorbidity of CML patients was hypertension, and the proportion of patients with other malignancies was relatively high in all treatment groups. 5-year OS was 77.1% during the whole study period. Patients initiating first-line TKI treatment for CML in 2015 had significantly better 4-year OS compared to those starting treatment in 2011 (82.4% vs. 73.5%, respectively, (HR 0.53 (95%CI 0.32–0.87) p = 0.0118).Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.https://www.por-journal.com/articles/10.3389/pore.2024.1611497/fullchronic myeloid leukemiareal-word evidencetyrosine kinase inhibitorstreatment outcomeoverall survival |
| spellingShingle | Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Zsolt Abonyi-Toth Judit Demeter Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary Pathology and Oncology Research chronic myeloid leukemia real-word evidence tyrosine kinase inhibitors treatment outcome overall survival |
| title | Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary |
| title_full | Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary |
| title_fullStr | Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary |
| title_full_unstemmed | Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary |
| title_short | Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary |
| title_sort | comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors a real world nationwide retrospective study from hungary |
| topic | chronic myeloid leukemia real-word evidence tyrosine kinase inhibitors treatment outcome overall survival |
| url | https://www.por-journal.com/articles/10.3389/pore.2024.1611497/full |
| work_keys_str_mv | AT peterbatar comorbiditiesandoutcomesofpatientswithchronicmyeloidleukemiatreatedwithtyrosinekinaseinhibitorsarealworldnationwideretrospectivestudyfromhungary AT hussainalizadeh comorbiditiesandoutcomesofpatientswithchronicmyeloidleukemiatreatedwithtyrosinekinaseinhibitorsarealworldnationwideretrospectivestudyfromhungary AT gyorgyrokszin comorbiditiesandoutcomesofpatientswithchronicmyeloidleukemiatreatedwithtyrosinekinaseinhibitorsarealworldnationwideretrospectivestudyfromhungary AT zsoltabonyitoth comorbiditiesandoutcomesofpatientswithchronicmyeloidleukemiatreatedwithtyrosinekinaseinhibitorsarealworldnationwideretrospectivestudyfromhungary AT zsoltabonyitoth comorbiditiesandoutcomesofpatientswithchronicmyeloidleukemiatreatedwithtyrosinekinaseinhibitorsarealworldnationwideretrospectivestudyfromhungary AT juditdemeter comorbiditiesandoutcomesofpatientswithchronicmyeloidleukemiatreatedwithtyrosinekinaseinhibitorsarealworldnationwideretrospectivestudyfromhungary |